Erratum: Combining active immunotherapy with immune checkpoint blockade for the treatment of advanced prostate cancer (Asian Journal of Andrology (2012) 14 (655) DOI: 10.1038/aja.2012.45);Combining active immunotherapy with immune checkpoint blockade for the treatment of advanced prostate cancer

Asian Journal of Andrology

Volumn 14, Issue 4, 2012, Pages 520-521

  Antonarakis, Emmanuel S ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; IPILIMUMAB; PROSTATE SPECIFIC ANTIGEN;

ACTIVE IMMUNIZATION; ADVANCED CANCER; ARTICLE; CANCER COMBINATION IMMUNOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; DRUG TOLERABILITY; HUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR IMMUNITY;

EID: 84863695808     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2012.61     Document Type: Erratum

References (9)

1. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ et al. Sipuleucel-T immunotherapy for castrationresistant prostate cancer. N Engl J Med 2010; 363: 411-22
2. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-23
3. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-26
4. Madan RA, Mohebtash M, Arlen PM, Vergati M, Rauckhorst M et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: A phase 1 dose-escalation trial. Lancet Oncol 2012; 13: 501-8
5. Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSAtargeted immunotherapy in metastatic castrationresistant prostate cancer. J Clin Oncol 2010; 28: 1099-10105
6. Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I et al. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res 2007; 13: 1810-5
7. Van Den Eertwegh AJ, Versluis J, van den Berg HP, Santegoets SJ, van Moorselaar RJ et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: A phase 1 dose-escalation trial. Lancet Oncol 2012; 13: 509-17
8. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28: 3167-75
9. Antonarakis ES, Drake CG. Combining immunological and androgen-directed approaches: An emerging concept in prostate cancer immunotherapy. Curr Opin Oncol 2012; 24: 258-65